Bioxytran Secures $1.6 million SPA to Extinguish Note & Fund Clinical Development
22 janv. 2025 09h00 HE
|
BIOXYTRAN, INC.
- Repurchasing all convertible note overhang, and - Funding pre-clinical and clinical trials - Management forfeiting $460,000 in accrued payroll BOSTON, MASSACHUSETTS, Jan. 22, 2025 (GLOBE...